Zale CEO DiNicola to Retire

Biogen remains lower as rival Sereno wins key drug approval; Albany Molecular drops; plus more of today's stocks in the news

RBC Capital reiterates outperform on Stellent (STEL ), saying business momentum is healthy, and the company is tracking to estimates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.